Document is current
Any future updates will be listed below
-
Authors
Parmeggiani, Francesco https://orcid.org/0000-0002-9296-0986
Weber, Michel
Bremond-Gignac, Dominique
Daly, Avril
Denee, Tom
Lahaye, Marjolein
Lotery, Andrew https://orcid.org/0000-0001-5541-4305
Paudel, Nabin https://orcid.org/0000-0003-1583-9856
Ritter, Markus
Rodríguez de la Rúa, Enrique
Rotenstreich, Ygal https://orcid.org/0000-0003-2366-1779
Sankila, Eeva-Marja
Stingl, Katarina
Van Denderen, Jacqueline
Pungor, Katalin https://orcid.org/0000-0003-4679-2050
-
Funding
Funding for this research was provided by:
Janssen Pharmaceutica N.V.
- License Information
-
More Information
Article History
Received: 31 May 2024
Revised: 26 November 2024
Accepted: 11 December 2024
First Online: 7 January 2025
Change Date: 27 January 2025
Change Type: Update
Change Details: In this article tab. 1 was not formatted correctly. This has been updated.
Competing interests
: MW, AL, MR and ERdlR have received consulting fees from Janssen and Novartis. FP has received consulting fees from AbbVie, Bayer, Janssen, Novartis and Roche. DB-G has received consulting fees from Alcon, Janssen, Novartis, Santen and Thea. AD, NP and E-MS have no competing interests. YR has received a consulting fee from Janssen. KS has received consulting fees to the University from Janssen, Novartis, ProQR Therapeutics, Santen and ViGeneron. ML, JVD, TD and KP are employees of Johnson and Johnson.
